新型口服抗凝药在房颤患者治疗中的研究进展

被引：8

作者：

束长城 ^{[1
]}

侯振世 ^{[2
]}

机构：

[1] 中央军委机关事务管理总局服务局保健室

[2] 北京市卫戍区第干休所门诊部

来源：

中国当代医药 | 2019年 / 26卷 / 04期

关键词：

房颤; 新型口服抗凝药; 华法林; 血栓栓塞性疾病;

D O I：

暂无

中图分类号：

R541.75 [];

学科分类号：

摘要：

房颤是常见的心律失常疾病之一,血栓栓塞性疾病是房颤最常见和最危险的并发症。口服传统抗凝药物华法林是预防房颤患者发生血栓栓塞性疾病的有效措施,但其治疗窗窄且易与多种药物和食物发生相互作用。新型口服抗凝药克服了华法林的上述缺点,能更好地预防房颤患者发生血栓栓塞性疾病及出血风险。现将新型口服抗凝药在房颤患者治疗中的研究进展作一综述。

引用

页码：26 / 28

页数：3

共 15 条

[1]

Edoxaban population pharmacokinetics and exposure–response analysis in patients with non-valvular atrial fibrillation [J].

Ophelia Q. P. Yin ;

Kimura Tetsuya ;

Raymond Miller .

European Journal of Clinical Pharmacology, 2014, 70 :1339-1351

[2]

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor [J].

Bounameaux, Henri ;

Camm, A. John .

DRUGS, 2014, 74 (11) :1209-1231

[3]

Worldwide Epidemiology of Atrial Fibrillation A Global Burden of Disease 2010 Study [J].

Chugh, Sumeet S. ;

Havmoeller, Rasmus ;

Narayanan, Kumar ;

Singh, David ;

Rienstra, Michiel ;

Benjamin, Emelia J. ;

Gillum, Richard F. ;

Kim, Young-Hoon ;

McAnulty, John H. ;

Zheng, Zhi-Jie ;

Forouzanfar, Mohammad H. ;

Naghavi, Mohsen ;

Mensah, George A. ;

Ezzati, Majid ;

Murray, Christopher J. L. .

CIRCULATION, 2014, 129 (08) :837-847

[4]

Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial [J].

Piccini, Jonathan P. ;

Stevens, Susanna R. ;

Lokhnygina, Yuliya ;

Patel, Manesh R. ;

Halperin, Jonathan L. ;

Singer, Daniel E. ;

Hankey, Graeme J. ;

Hacke, Werner ;

Becker, Richard C. ;

Nessel, Christopher C. ;

Mahaffey, Kenneth W. ;

Fox, Keith A. A. ;

Califf, Robert M. ;

Breithardt, Guenter .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (19) :1998-2006

[5]

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy [J].

Brignole, Michele ;

Auricchio, Angelo ;

Baron-Esquivias, Gonzalo ;

Bordachar, Pierre ;

Boriani, Giuseppe ;

Breithardt, Ole-A ;

Cleland, John ;

Deharo, Jean-Claude ;

Delgado, Victoria ;

Elliott, Perry M. ;

Gorenek, Bulent ;

Israel, Carsten W. ;

Leclercq, Christophe ;

Linde, Cecilia ;

Mont, Llus ;

Padeletti, Luigi ;

Sutton, Richard ;

Vardas, Panos E. ;

Zamorano, Jose Luis ;

Achenbach, Stephan ;

Baumgartner, Helmut ;

Bax, Jeroen J. ;

Bueno, Hctor ;

Dean, Veronica ;

Deaton, Christi ;

Erol, Cetin ;

Fagard, Robert ;

Ferrari, Roberto ;

Hasdai, David ;

Hoes, Arno W. ;

Kirchhof, Paulus ;

Knuuti, Juhani ;

Kolh, Philippe ;

Lancellotti, Patrizio ;

Linhart, Ales ;

Nihoyannopoulos, Petros ;

Piepoli, Massimo F. ;

Ponikowski, Piotr ;

Sirnes, Per Anton ;

Tamargo, Juan Luis ;

Tendera, Michal ;

Torbicki, Adam ;

Wijns, William ;

Windecker, Stephan ;

Kirchhof, Paulus ;

Blomstrom-Lundqvist, Carina ;

Badano, Luigi P. ;

Aliyev, Farid ;

Bnsch, Dietmar ;

Baumgartner, Helmut .

EUROPACE, 2013, 15 (08) :1070-1118

[6]

Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50;578 patients.[J].Davide Capodanno;Piera Capranzano;Giuseppe Giacchi;Valeria Calvi;Corrado Tamburino.International Journal of Cardiology.2012,

[7]

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial [J].